Larynx verrucous carcinoma
disease diseaseOn this page
Also known as laryngeal throat verrucous cancerlaryngeal verrucous carcinomaverrucous carcinoma of larynxverrucous carcinoma of the larynx
Summary
Larynx verrucous carcinoma (MONDO:0002766) is a cancer and 48 clinical trials. Top therapeutic interventions include cisplatin, sorafenib, and lapatinib. A subtype of laryngeal squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 48
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | larynx verrucous carcinoma |
| Mondo ID | MONDO:0002766 |
| DOID | DOID:3752 |
| NCIT | C8188 |
| SNOMED CT | 707427000 |
| UMLS | C0280328 |
| MedGen | 76097 |
| GARD | 0023239 |
| Anatomy (UBERON) | UBERON:0001737 |
| Is cancer (heuristic) | yes |
Also known as: laryngeal throat verrucous cancer · laryngeal verrucous carcinoma · larynx verrucous carcinoma · verrucous carcinoma of larynx · verrucous carcinoma of the larynx
Disease family
This is a subtype of laryngeal squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › larynx cancer › laryngeal carcinoma › laryngeal squamous cell carcinoma › larynx verrucous carcinoma
Related subtypes (3): glottis squamous cell carcinoma, subglottis squamous cell carcinoma, supraglottis squamous cell carcinoma
Subtypes (3): glottis verrucous carcinoma, subglottis verrucous carcinoma, supraglottis verrucous carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 48.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 20 |
| PHASE1 | 17 |
| Not specified | 7 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00588770 | PHASE3 | ACTIVE_NOT_RECRUITING | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT00033618 | PHASE2 | COMPLETED | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck |
| NCT00095628 | PHASE2 | COMPLETED | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00096512 | PHASE2 | COMPLETED | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00101348 | PHASE1/PHASE2 | COMPLETED | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer |
| NCT00103259 | PHASE2 | COMPLETED | Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| NCT00114283 | PHASE2 | COMPLETED | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
| NCT00458978 | PHASE2 | COMPLETED | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer |
| NCT00492089 | PHASE2 | COMPLETED | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
| NCT00507767 | PHASE2 | COMPLETED | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00513435 | PHASE2 | COMPLETED | Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00939627 | PHASE2 | COMPLETED | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab |
| NCT01044433 | PHASE2 | COMPLETED | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck |
| NCT01192815 | PHASE2 | TERMINATED | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck |
| NCT01256385 | PHASE2 | COMPLETED | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy |
| NCT01316757 | PHASE2 | COMPLETED | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| NCT01469429 | PHASE1/PHASE2 | COMPLETED | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. |
| NCT01674374 | PHASE2 | WITHDRAWN | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy |
| NCT01816984 | PHASE1/PHASE2 | COMPLETED | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT02007200 | PHASE2 | COMPLETED | Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery |
| NCT02048020 | PHASE2 | COMPLETED | Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer |
| NCT02068157 | PHASE2 | TERMINATED | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer |
| NCT02123511 | PHASE2 | COMPLETED | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy |
| NCT02196168 | PHASE2 | TERMINATED | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00023959 | PHASE1 | COMPLETED | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer |
| NCT00030498 | PHASE1 | COMPLETED | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
| NCT00031681 | PHASE1 | COMPLETED | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
| NCT00049283 | PHASE1 | COMPLETED | Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer |
| NCT00089362 | PHASE1 | COMPLETED | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors |
| NCT00397384 | PHASE1 | COMPLETED | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer |
| NCT00470496 | PHASE1 | COMPLETED | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer |
| NCT00906360 | PHASE1 | TERMINATED | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
| NCT01249443 | PHASE1 | TERMINATED | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection |
| NCT01254617 | PHASE1 | COMPLETED | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer |
| NCT01332279 | PHASE1 | WITHDRAWN | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy |
| NCT01334177 | PHASE1 | COMPLETED | TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck |
| NCT01528137 | PHASE1 | TERMINATED | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer |
| NCT01637194 | PHASE1 | COMPLETED | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer |
| NCT01728480 | PHASE1 | WITHDRAWN | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy |
| NCT01847326 | PHASE1 | COMPLETED | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 5 |
| SORAFENIB | 4 | 4 |
| LAPATINIB | 4 | 3 |
| DASATINIB ANHYDROUS | 4 | 2 |
| ERLOTINIB HYDROCHLORIDE | 4 | 1 |
| IXABEPILONE | 4 | 1 |
| PORFIMER SODIUM | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| SARACATINIB | 3 | 1 |
| TALACTOFERRIN ALFA | 3 | 1 |
| ENTOLIMOD | 2 | 1 |
| HPPH | 2 | 1 |
| ISPINESIB | 2 | 1 |
| SOY ISOFLAVONES | 2 | 1 |
| UCN-01 | 2 | 1 |
| ALVESPIMYCIN HYDROCHLORIDE | 1 | 1 |
| CHEMBL2326523 | 0 | 1 |
| CHEMBL4583196 | 0 | 1 |
| CHEMBL4438584 | 0 | 1 |
| CHEMBL1236539 | 0 | 1 |